Loading
Bio-Gate AG Stock: price and insider trades · Germany
Bio-Gate AG: what insiders have been doing
This page follows insider dealings at Bio-Gate AG as filed with BaFin, a company from the Healthcare & Pharma sector. Between 18 October 2025 and 18 October 2026, 2 insiders published 2 filings.
The filings describe grants, exercises and other transfers rather than trades on the open market. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
No insider has bought Bio-Gate AG shares on the open market in the past twelve months.
Compared with its exchange (287 companies, median 5 filings), a count of 2 filings is below the norm.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by BaFin. They describe what insiders did and are not a recommendation.
Insider Decl.
4
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
n/a
n/a
Fundamental score
Ranked 22,855 of 24,158 companies
16.3
score / 100
Value2
Quality31
FCF yld-107%
Earn yld-88%
EV/EBITDA·
ROE-72%
Gross mgn58%
Net mgn-16%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€0.65
Analyst consensus
Income statement
Revenue€7.4M
Gross profit€4.3M58% margin
EBITDA-€895k-12% margin
Net income-€1.2M-15.1% margin
Valuation
P/Book4.3x
Beta0.02
Balance sheet & cash
Market cap€1.3M
Total debt€53k
Free Cash Flow-€1.4M
Debt / Equity54%
Profitability & ownership
ROE-72.0%
ROA-16.4%
% insiders234.4%
% institutions48.1%
Last declaration on 7 August 2026
Declarations4 total
Other financial instr. linked to share;debt instr.BAFIN:40004794-0fbad561431a
107,143 shares@ €2.8022.64% mcap73.2% of flowShareISIN DE000BGAG0J3BAFIN:40004794-f206e5140b82
11 shares@ €10,000.0026.8% of flowDebt instrumentBAFIN:40004794-7bc197c98f87
1 shares@ €50,000.00100.0% of flowDebt instrumentBAFIN:40004794
4 of 4 declarations
About Bio-Gate AG
Bio-Gate AG is a German healthcare technology company listed on Xetra/Frankfurt (DAX/MDAX/SDAX), operating as a niche specialist at the intersection of human health, animal health, and surface hygiene. Headquartered in Germany, with operating sites in Nuremberg and Bremen, the company develops and commercializes antimicrobial and antiviral solutions designed to improve safety in hygiene-sensitive environments. Its business model is based on the monetization of proprietary technologies applied to materials, products, and surfaces, rather than on the sale of conventional pharmaceuticals.
Founded in the early 2000s, Bio-Gate has built its expertise around two core technology platforms. The first is HyProtect™, an ultrathin plasma coating designed to reduce bacterial colonization on medical implants, particularly in orthopaedics. The second is MicroSilver BG™, an antimicrobial and antiviral additive that can be integrated into a wide range of materials and formulations. This technological base allows the group to address several end markets: medical devices, dermatological care and wound management, veterinary products, and industrial/consumer hygiene applications.
Read moreShow less
From a competitive standpoint, Bio-Gate is differentiated less by scale than by specialization, intellectual property, and its ability to industrialize niche solutions with added value. The company collaborates with universities and research institutes and operates an independent microbiological testing subsidiary, QualityLabs BT GmbH, which strengthens the scientific credibility of its development work. In parallel, Bio-Gate is expanding veterinary products through VetInnovations, with increasing commercial reach in Europe and North America.
Recent disclosures point to gradual operational improvement. In 2025, the company reported an expanded North American presence in veterinary care, while clinical data supported the commercialization of medical CBD-based care products. In December 2024, Bio-Gate announced a key step toward serial production of HyProtect™-coated orthopaedic implants, with a clinical study underway for CE approval. For fiscal 2025, the company reported in April 2026 revenue of EUR 7.4 million and a narrower net loss, indicating that operating leverage is developing, albeit from a still modest base. For investors, Bio-Gate remains a German micro/small-cap innovation story exposed to attractive end markets, but still in the scaling phase.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
